Статини для профілактики АССЗ
Classification | Effects* | Recommended For | Examples† |
|---|---|---|---|
High-intensity | Lowers LDL-C ≥ 50% | Clinical ASCVD, age ≤ 75 years LDL-C ≥ 190 mg/dL (4.9 mmol/L) Age 40 to 75 years, 10-year ASCVD risk ≥ 7.5% Diabetes and 10-year ASCVD risk ≥ 7.5% | Atorvastatin 40-80 mg Rosuvastatin 20-40 mg |
Moderate-intensity | Lowers LDL-C 30 to < 50% | Clinical ASCVD, age > 75 years Age 40 to 75 years, 10-year ASCVD risk 5 to < 7.5% Age 40 to 75 years, 10-year ASCVD risk ≥ 7.5% (if unable to tolerate high-intensity statin) Diabetes and 10-year ASCVD risk < 7.5% | Atorvastatin 10-20 mg Fluvastatin XL 80 mg Lovastatin 40 mg Pitavastatin 2-4 mg Pravastatin 40-80 mg Rosuvastatin 5-10 mg Simvastatin 20-40 mg |
Low-intensity | Lowers LDL-C < 30% | Patients who cannot tolerate high or moderate intensity treatment | Fluvastatin 20-40 mg Lovastatin 20 mg Pitavastatin 1 mg Pravastatin 10-20 mg |
* Individual response may vary. | |||
† All doses are oral and given once daily. | |||
ASCVD = atherosclerotic cardiovascular disease; LDL-C = low density lipoprotein cholesterol. | |||
Adapted from Stone NJ, Robinson J, Lichtenstein AH, et al: 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation 129:S1–S45, 2014. | |||